IMAB - I-Mab Biopharma Non-GAAP EPADS of -$3.58 misses by $2.75 revenue of $32.1M misses by $69.23M
2023-03-31 06:43:48 ET
- I-Mab Biopharma press release ( NASDAQ: IMAB ): FY Non-GAAP EPADS of -$3.58 misses by $2.75 .
- Revenue of $32.1M (vs.$13.8M Y/Y) misses by $69.23M .
- A strong cash position of $514.2M by the end of 2022, sufficient to fund key business operations for the next three years.
For further details see:
I-Mab Biopharma Non-GAAP EPADS of -$3.58 misses by $2.75, revenue of $32.1M misses by $69.23M